Stock Ratings / Health Care / GMAB / earnings

RPRX (75) ZTS (67) ONC (71) ROIV (44) ⌘ Pro Terminal →

Genmab A/S ADS (GMAB) Next Earnings Date & Expected ±11.2% Move

$56.49 -1.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Genmab A/S ADS (GMAB) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (steady margins, 10% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $35.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GMAB)Realized 20D OHLCV Swing Band: ±11.2%

NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±11.2% Swing Band

±$6.33 Expected Swing

MODEL EARNINGS SETUP GAUGE

GMAB Quantitative Pre-Earnings Setup: 70/100

Trailing EPS: $1.72 • YoY Revenue Growth: 22%

Model Bullish Setup (70/100)Model Risk Weight (30/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating GMAB & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on GMAB
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GMAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +108.91%▲ ASCENDING CHANNEL

2026-11-01O $57.29H $57.29L $56.49C $56.49VOL 6.25M

RES: $60.85SUP: $36.42SMA50: $37.58SMA200: $30.62

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GMAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GMAB Butterfly Map → + Track GMAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +22.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GMAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GMAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GMAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GMAB)

Health Care Rank #66 of 188 ⚔️ RPRX vs GMAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GMAB vs. RPRX, ZTS, ONC, ROIV)

Industry: Biotechnology: Pharmaceutical Preparations (64 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Genmab A/S ADS (GMAB) ranks #66 by composite RQD confidence (70/100, grade B-) and #52 by equity capitalization ($35.25B). Within this direct 5-issuer industry benchmark cohort, ZTS leads on earnings valuation at 12.2x trailing P/E, while ZTS leads on capital efficiency and profitability with 25.7% ROIC and 71.8% gross margin. RPRX currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with GMAB at 70/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GMAB ACTIVE Genmab A/S ADS	B-	70/100	32.8x	—	9.9%	-1.40%	$35.25B	Benchmark Subject
RPRX Royalty Pharma plc (Class A)	B	75/100	49.2x	—	7.0%	+1.71%	$37.91B	/rprx-vs-gmab →
ZTS Zoetis Inc.	C+	67/100	12.2x	71.8%	25.7%	+1.29%	$32.56B	/zts-vs-gmab →
ONC BeOne Medicines Ltd.	B-	71/100	147.2x	87.5%	10.5%	-0.48%	$42.25B	/onc-vs-gmab →
ROIV Roivant Sciences Ltd.	D	44/100	—	—	-14.0%	+1.11%	$27.10B	/roiv-vs-gmab →

2. GMAB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Genmab A/S ADS (GMAB) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $35.25B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. GMAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GMAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Genmab A/S ADS (NASDAQ: GMAB) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $56.49 (-1.40% 1D, market cap $35.25B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 188 tracked Health Care issuers, GMAB ranks #66 in composite RQD confidence.

How does GMAB compare to RPRX and ZTS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GMAB carries a Roarable B- (70/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, RPRX (Royalty Pharma plc (Class A)) holds a B grade (75/100 RQD, P/E 49.2x, ROIC 7.0%, cap $37.91B) and ZTS (Zoetis Inc.) posts a C+ grade (67/100 RQD, P/E 12.2x, ROIC 25.7%, cap $32.56B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GMAB?

For Genmab A/S ADS (GMAB), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GMAB trading relative to its 50-day, 200-day, and 52-week technical levels?

GMAB last traded at $56.49 (-1.40% on volume of 6,253,488 shares), positioning the stock +50.32% above its 50-day simple moving average ($37.58) and +84.49% above its 200-day simple moving average ($30.62). Across its 52-week range of $23.62 to $59.97, GMAB sits at the 90.4% percentile with a 14-day RSI of 85.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±11.2% ($50.16 to $62.82).